Exelixis (NASDAQ:EXEL) Now Covered by Brookline Capital Management

Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL) in a research report issued to clients and investors on Monday, MarketBeat reports. The brokerage set a “buy” rating on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Bank of America cut Exelixis from a “buy” rating to a “neutral” rating and boosted their target price for the company from $35.00 to $39.00 in a research note on Tuesday, December 17th. UBS Group began coverage on Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 target price for the company. Guggenheim lifted their price target on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. HC Wainwright reiterated a “buy” rating and issued a $29.00 price target on shares of Exelixis in a report on Wednesday, September 18th. Finally, JMP Securities restated a “market outperform” rating and set a $29.00 price objective on shares of Exelixis in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Exelixis currently has an average rating of “Moderate Buy” and a consensus target price of $32.44.

Exelixis Price Performance

Exelixis stock opened at $33.82 on Monday. The firm has a market capitalization of $9.66 billion, a price-to-earnings ratio of 21.68, a PEG ratio of 0.89 and a beta of 0.52. The company’s 50 day simple moving average is $33.76 and its 200 day simple moving average is $27.79. Exelixis has a fifty-two week low of $19.20 and a fifty-two week high of $36.97.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.36 by $0.04. Exelixis had a net margin of 22.43% and a return on equity of 20.99%. The company had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same period last year, the business posted $0.10 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. As a group, analysts predict that Exelixis will post 1.69 EPS for the current fiscal year.

Insider Activity at Exelixis

In other Exelixis news, EVP Jeffrey Hessekiel sold 25,000 shares of the company’s stock in a transaction on Monday, October 28th. The shares were sold at an average price of $28.39, for a total transaction of $709,750.00. Following the sale, the executive vice president now directly owns 580,325 shares of the company’s stock, valued at approximately $16,475,426.75. This represents a 4.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at approximately $15,666,873. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 314,736 shares of company stock valued at $10,849,110. Insiders own 2.85% of the company’s stock.

Institutional Trading of Exelixis

A number of hedge funds have recently made changes to their positions in EXEL. V Square Quantitative Management LLC bought a new stake in Exelixis in the 3rd quarter valued at $30,000. Brooklyn Investment Group acquired a new position in shares of Exelixis in the third quarter valued at $42,000. Capital Performance Advisors LLP bought a new position in shares of Exelixis in the third quarter valued at about $61,000. Essex Investment Management Co. LLC acquired a new stake in shares of Exelixis during the 3rd quarter worth about $74,000. Finally, GAMMA Investing LLC lifted its stake in shares of Exelixis by 50.0% during the 3rd quarter. GAMMA Investing LLC now owns 3,010 shares of the biotechnology company’s stock worth $78,000 after buying an additional 1,004 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.